Publications by authors named "S Begbie"
Article Synopsis
- This clinical trial tested the effectiveness of an oral cannabis extract (THC:CBD) on adults experiencing severe nausea and vomiting from chemotherapy, despite using standard anti-nausea medications.
- The results showed that the cannabis extract significantly increased the rate of complete responses (no vomiting or need for rescue meds) from 8% to 24% compared to a placebo.
- While participants reported some mild side effects like sedation and dizziness, there were no serious adverse events linked to the cannabis treatment.
Article Synopsis
- The study aimed to assess the effectiveness of adding ipilimumab to nivolumab treatment in patients with advanced, non-clear-cell renal cell carcinoma who showed disease progression on nivolumab alone.
- In a phase 2 trial, patients received nivolumab for up to 12 months, then ipilimumab if their condition worsened; the response rates were relatively low, with notable treatment-related adverse events.
- Despite modest overall effects of nivolumab alone, some participants did respond well, and the combination treatments continued to show some promise in managing the disease.
Background: There is an immunologic rationale to evaluate immunotherapy in the older glioblastoma population, who have been underrepresented in prior trials. The NUTMEG study evaluated the combination of nivolumab and temozolomide in patients with glioblastoma aged 65 years and older.
Methods: NUTMEG was a multicenter 2:1 randomized phase II trial for patients with newly diagnosed glioblastoma aged 65 years and older.
Purpose: There is an unmet need for therapeutic options that prolong survival for patients with heavily pretreated, metastatic castration-resistant prostate cancer (mCRPC). The phase III, open-label KEYLYNK-010 study evaluated pembrolizumab plus olaparib versus a next-generation hormonal agent (NHA) for biomarker-unselected, previously treated mCRPC.
Methods: Eligible participants had mCRPC that progressed on or after abiraterone or enzalutamide (but not both) and docetaxel.
Background: The interim analysis of the ENZAMET trial of testosterone suppression plus either enzalutamide or standard nonsteroidal antiandrogen therapy showed an early overall survival benefit with enzalutamide. Here, we report the planned primary overall survival analysis, with the aim of defining the benefit of enzalutamide treatment in different prognostic subgroups (synchronous and metachronous high-volume or low-volume disease) and in those who received concurrent docetaxel.
Methods: ENZAMET is an international, open-label, randomised, phase 3 trial conducted at 83 sites (including clinics, hospitals, and university centres) in Australia, Canada, Ireland, New Zealand, the UK, and the USA.